Bivalirudin
Direct thrombin inhibitor for PCI anticoagulation. Reversible hirudin analog with rapid onset and offset, ideal for percutaneous coronary intervention and heparin-induced thrombocytopenia (HIT) management.
Bivalirudin is a synthetic 20-amino acid peptide and a direct thrombin inhibitor used as an anticoagulant in percutaneous coronary intervention (PCI) and for the treatment of heparin-induced thrombocytopenia (HIT). It consists of a hirudin-like N-terminal domain that binds to thrombin’s active site and a C-terminal domain that interacts with the fibrinogen recognition exosite, providing rapid and predictable anticoagulation with a short half-life.
| Parameter | Specification |
| CAS | 128270-60-0 |
| Molecular Formula | C₉₈H₁₃₈N₂₄O₃₃ |
| Molecular Weight | 2180.29 g/mol |
| Category | Cardiovascular |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | PCI anticoagulation, HIT, thrombosis prevention, acute coronary syndrome |
| CAS | 128270-60-0 |
|---|---|
| Applications | Ischemic Complication Control, Percutaneous Coronary Intervention, Thrombosis Prevention |
Related products
-
Tirzepatide
CAS: 2023788-19-2Applications: Advanced obesity, metabolic syndrome, Type 2 diabetes -
Glucagon HCl
CAS: 16941-32-5Applications: Diabetic Emergency, Glycogenolysis, Hypoglycemia Rescue -
Apraglutide
CAS: 1295353-98-8Applications: GLP-2, Intestinal Repair, Mucosal Growth, Short Bowel Syndrome -
GLP-1 (7-37)
CAS: 106612-94-6Applications: Diabetes Research, GLP-1 Analog Development, metabolic syndrome